Aberdeen Healthcare Investors (HQH) is a biotech-focused closed-end fund trading at a 6.4% discount to its net asset value (NAV). Over the past year, the fund delivered a strong 56% NAV return, benefiting from favorable FDA regulatory changes and merger and acquisition activity. It offers a near-12% distribution rate, fully funded by realized gains rather than return of capital, which is notable among high-payout funds. However, risks include exposure to volatile biotech ventures, payout sustainability, and sector cyclicality, making careful position sizing and tax planning important for investors.
Lighter (LIT) has surged to a three-week high of $2.4, up 9.23% on strong daily trading volume growth of 53% to $49 million. A major whale investor has spent $9.1 million over two months to accumulate 3.91 million LIT, including a recent $1 million p...
Lido revealed a bug during the rollout of Staking Router v3 where an AccountingOracle error missed a 32 ETH validator deposit, causing an incorrect stETH rebase rate of 2.04% APR. This issue occurred during the upgrade from a per-validator reward sys...
Pacific Empire Minerals Corp. has granted a total of 6.8 million Restricted Share Units (RSUs) and 17.7 million Stock Options to its directors, officers, and consultants under its equity incentive plan. Most of these grants, 16.7 million options and ...
Allianz reported a record operating profit of €4.87 billion in Q2 2026, a 10.6% increase year-over-year, driven by strong asset management and life and health segments. Despite this, shareholders' core net income declined by 8.7% to €2.60 billion, mi...
Quantum Corporation is set to report earnings on August 10, 2026, with analysts expecting a loss of $0.15 per share and revenue of $75.05 million. The company shows signs of financial strain, including a negative price-to-earnings ratio of -1.45 and ...
